Meet our Team

From our staff to our board of directors, we are led by a driven community of scientists, fundraisers, affiliates and ambassadors who share an unwavering commitment to end ALS. Every day we are challenging conventions. Every day we are collaborating with people living with ALS. Every day we are closer to removing the death sentence from ALS.

Bashar joined the ALS Therapy Development Institute in 2005 initially as the Director of Bioinformatics. Today, as Vice President of Information Technology, he oversees the organization’s technical infrastructure and internal technology systems. Bashar has over 22 years of experience in software development, information systems, and managing cross-functional teams. Prior to joining the Institute, Bashar was the Director of Development at IMN INC, a leading e-marking global company. Bashar has also held roles as a technology advisor and consultant to various start-ups, large companies such as EMD Serono, and non-profits such as Youth Build USA, and Urban League of Eastern Massachusetts. Earlier in his career, Bashar spent several years working at Microsoft and, where he was involved in developing some of their earlier products. Bashar holds an MBA from Northeastern University, and a Software Engineering and Computer Science degrees from the University of Washington and Wentworth Institute of Technology respectively.
Kaycee joined ALS Therapy Development Institute in 2018. In her role as Data & Stewardship Coordinator, Kaycee focuses on supporting the lead management team and donor relations. Originally from Rhode Island, she stayed local for college attending Bryant University where she played one year of Division I Lacrosse and majored in marketing. Starting internships in high school in many different areas, including senator campaigns and marketing for the Red Sox, Kaycee came to ALS TDI looking for a role in which she would be contributing to a greater cause. Recently, Kaycee just starred in a commercial for a local waste disposal company!

“There is nothing in the world so irresistibly contagious as laughter and good humor." - Charles Dickens
Kelly Campbell joined the ALS Therapy Development Institute in 2014. Kelly plays key roles in our fitness industry fundraising initiatives, as well as working on Augie's Quest signature events including The BASH and Tradition of Hope Gala. Kelly has over 17 years in non-profit experience, including working with Augie's Quest for the past 9 years. She has worked closely with Augie and Lynne Nieto on raising over $50 million for ALS research. Kelly resides in San Diego, CA with her husband and four children.
Isarelis (Isa) J. Carrion joined the ALS Therapy Development Institute in September, 2007 and is part of the Histology team. This team specializes in processing frozen tissues to provide scientists with tissue section slides, so they can used them as secondary screening assays. Isa loves to work at the Institute because we always put the patients first and our mission is simple - to find a cure for ALS as soon as possible. Isa earned her BS in Biology at UMass Boston. She lives with her three beautiful boys in Cambridge, MA.
Tanille Carter joined the ALS Therapy Development Institute in 2018 as the Senior Director of Development for the western United States. In her role, she collaboratively develops ALS TDI's fundraising strategies, provides support and insight to those fundraising on behalf of ALS TDI and ensures families are informed and connected to the research happening in Cambridge. Prior to joining ALS TDI, she served as the Executive Director for MDA’s Metropolitan Los Angeles and Southland District. Tanille eagerly joined ALS TDI to help fulfill a sense of responsibility and commitment to urgently deliver an effective treatment to people living with ALS. Tanille is proud graduate of Clark Atlanta University where she received a Bachelors in Mass Media Arts and Public Relations. Tanille is a Southern California native that lives in the coastal community of San Pedro with her dog Sasha. She enjoys any place that is full of laughter, spending as much time as possible at the beach, taking Sasha to the dog park, playing scrabble, traveling and spending as much time as possible with family. Her cell phone is programmed to ask daily at noon if she is living Philippians 2:3-4, “Do nothing out of selfish ambition or vain conceit. Rather, in humility value others above yourselves, not looking to your own interests but each of you to the interest of others.”
Taylor Charbonneau joined the ALS Therapy Development Institute in 2018. She is the point of contact for patients involved in the Precision Medicine Program and manages the accelerometers used in the program’s research. Taylor is inspired by the strength of people living with ALS as well as their families, and loves being able to offer them support on both their best days and worst days. Earlier in 2018, Taylor graduated from James Madison University with a B.S. in Health Services Administration and a minor in Medical Spanish. She has a passion for fitness and wellness, loves to travel, and is happiest when spending time with her three roommates and her dog, Brady.

“Act as if what you do makes a difference. It does.” – William James
Xiaoying Chen (Nicole) joined the ALS Therapy Development Institute as part of the Translational Research group in 2018. She brings her passion for cell and molecular biology to work on assay development and drug screening with patient-derived cell lines. Four years ago, Nicole left Shanghai, China to Boston for University. She is a recent graduate from Northeastern University with a Bachelor Degree with honors of Science in Biology and minors in Math and Business. Besides education, she did a direct study on gene therapy with her Professor Ke Zhang for three years and had one publication as a co-author; also, she did a Co-Op at Neon Therapeutics in Molecular Immunology group. Coming with research experience of immunology, and cell and molecular biology, she wants to contribute to curing ALS as part of the team of ALS TDI. Besides research, she enjoyed cooking, playing Guzheng (a traditional Chinese instrument) and sports including sailing, swimming, hiking, and basketball.
Dr. Kyle Denton joined the ALS Therapy Development Institute in 2016. He is currently working on establishing high-throughput methods for generating neural subtypes from patient induced pluripotent stem cells to use in phenotype discovery and drug screening studies. Kyle joined the Institute because of his interest in neurodegenerative research and the opportunity to work with the resources that the Precision Medicine Program provides. He came to the Institute after a postdoctoral position in Dr. Jennifer Lippincott-Schwartz’s lab at the National Institutes of Health. Kyle received his Ph.D. from the University of Connecticut Health Center in Biomedical Sciences, with a concentration in neuroscience. Prior to that, he received his B.A. and M.A. from Clark University in Biochemistry and Molecular Biology in 2010 and 2011, respectively. In his free time, Kyle enjoys cycling and hiking.
Emily joined the ALS Therapy Development Institute in 2017 after moving up to Boston. As the Digital and Social Media Specialist, she spends her days sharing the stories of people living with ALS and the scientific discoveries of ALS TDI with the world. Emily is originally from Tampa and graduated from the University of Florida with a Bachelor of Science in Advertising in 2014. In her free time she enjoys traveling, eating, running, laughing, and spending time with friends and family. “Embrace the glorious mess that you are” - Elizabeth Gilbert
Ben Engle joined the ALS Therapy Development Institute in 2012. As a Development Director, Ben raises money and awareness to support the vital research being done at the Institute. He feels honored to have the privilege of working alongside the many intelligent and dedicated people at the Institute who are 100% committed to finding a cure for ALS. Prior to joining the team, Ben spent several years working as a professional chef. He graduated from Northeastern University in 2010 with a bachelor's degree in Political Science and a minor in International Affairs. Ben has enjoyed living in Boston since 2005 and currently resides in Dorchester with his wife, Molly. “…plans are useless, but planning is indispensable.” - Dwight D. Eisenhower
Caitlin Faulds joined the ALS Therapy Development Institute in 2017. She was struck by how committed the team at ALS TDI is to progressing research and is proud to be part of such a unique and diverse group. As part of the finance team she supports donor communication and makes sure that all donations get where they need to go. Before joining ALS TDI, Caitlin studied social anthropology at the University of St Andrews, Scotland. Her experience with fundraising began here when she led a student charity trek to Mt Kilimanjaro for Worldwide Cancer Research. After graduating, she moved to the woods of Western Massachusetts to join an AmeriCorps group doing environmental education and trail work in parks around the state. In her free time she enjoys hiking, playing violin, and traveling and camping when she can. "Of all the paths you take in life, make sure a few of them are dirt." - John Muir
Matt Ferola joined the ALS Therapy Development Institute in 2003. Having lost his grandmother's cousin to ALS, Matt has been a dedicated member of the animal care team here at the institute. His primary goal is to maintain the animal facility and provide clean and healthy environments for all of the mice involved in research studies. Matt grew up in Somerville, Massachusetts and pursued a certificate in graphic communications before joining the research staff at the Institute.
Anna Gill joined the ALS Therapy Development Institute in 2015. She started as a part-time research intern while completing her Bachelor's degree, and transitioned to a full-time scientist on the In-vivo team starting in 2018. Her current focus is studying the biological mechanisms of C9ORF72-ALS pathology using newly-developed cell-based models and assays. Anna graduated cum laude from Emmanuel College with a B.S. in Biology concentrating in Health Sciences, and intends to pursue a graduate degree. As a full time student and part time intern, she wrote and defended an undergraduate thesis titled "Investigating cellular effects of neurodegeneration-associated peptides in C9ORF72 ALS" based on research done at ALS-TDI. Her parents Alan and Cindy Gill have worked at ALS TDI for over 10 years, which gave her a unique opportunity to watch the institute grow from the ground up. She continues to be humbled and inspired by those living with ALS, their families, and her coworkers, who give everything they have to make this lab a life-changing powerhouse to grow in.

"Look up at the stars and not down at your feet." – Stephen Hawking
Cindy Gill joined ALS Therapy Development Institute in 2008. Cindy received an undergraduate degree in Biology from Simmons College and spent 15 years in Research at biotechnology companies, including 9 years at Biogen. She was involved primarily in the discovery and testing of Immunology-based therapeutics, and has an extensive background in monoclonal antibody production and the in-vitro/in-vivo characterization of potential drugs. She took a break from biotech to nearly complete a second degree from Simmons in Nursing and to be home with her two children, Anna and Joe. At the Institute, Cindy works in the Pharmacology group to help evaluate in-vivo drug effects in the G93A model.
Dr. Alan Gill joined the ALS Therapy Development Institute in 2007. He is an experienced pharmacologist/physiologist with a thorough understanding of practical investigation in complex in vivo animal systems. He came to the Institute after a one-year immersion in Huntington's disease drug discovery as the Director and Head of Pharmacology at EnVivo Pharmaceuticals, a biotechnology company concentrating on neurodegenerative diseases. Prior to EnVivo he worked for 13 years in Biogen and Biogen Idec's drug discovery research division where he instituted Biogen's Pharmacology Department. These efforts led to drug candidates that were the basis for collaboration with Merck and Co. for their clinical development, and to small molecule and protein potential therapeutics selected for development by Biogen Idec itself. Prior to working for Biogen, Alan worked for 12 years with Johnson & Johnson's worldwide drug discovery research division. He received his Ph.D. in Pharmacology from the M.S. Hershey Medical Center of the Pennsylvania State University, and his Master's degree in Physiology and Bachelor's degree in Biology from the University of San Francisco.
Alicia Grossi joined the ALS Therapy Development institute in 2006. Her grandfather missed a lifetime when he died of ALS at age 51. She wants to change that for people facing ALS today. Alicia graduated from Quinnipiac University with a degree in Advertising and began fundraising, event planning and marketing as an intern for the Tri-State Trek. In her role as Director of Donor Communications & Stewardship, Alicia manages comprehensive donor relations and our stewardship program, interacting with 35,000 annual donors. She has diverse experience in donor development, stewardship, marketing/communications and fundraising events. “It is the enduring pursuit of a goal, not the fleeting glory of the finish line, that shapes the lasting victories within us.” ~ unknown
Carol Hamilton joined ALS Therapy Development Institute in 2005. After a friend’s brother passed away of ALS, she joined first as a volunteer consultant, working on Capitol Hill to increase our federal funding. Carol worked closely with Congressional leaders, the Department of Defense, and the Department of Veterans Affairs to secure over $6M in contracts for the Institute. As Senior Director of Development, Carol works with foundations and donors to accelerate our work. Prior to joining ALS Therapy Development Institute, Carol was an executive at Saks Fifth Avenue, and ran a small company of her own. Carol studied at Oxford University, and graduated from the Georgetown University School of Business. She lives in Sherborn, and is the proud mother of two incredible young women. “If you stand for nothing, Burr, what will you fall for?” ~Lin Manuel Miranda
Terri Handler joined the ALS Therapy Development Institute in 2011, 7 months after she lost her brother to ALS. As a Development Director, Her job, along with a dedicated team, requires securing the urgent funding needed to move our research ahead as fast as possible. Her journey began in 2007 when she witnessed this disease firsthand but her work continues today for all the current ALS families to stop the pain and suffering and see an end to ALS. Terri’s brother is never far from her mind and she remembers him always saying his life was great but just too short. "You can’t have a better tomorrow if you are always thinking about yesterday" ~ Author Unknown
Dr. Theo Hatzipetros joined the ALS Therapy Development Institute in 2011. He is an in vivo pharmacologist who specializes in the field of neurodegeneration. Prior to joining the Institute, Theo worked on drug discovery for the treatment of Parkinson's Disease at FoldRx Pharmaceuticals. At the ALS Therapy Development Institute, Theo's efforts are focused on the development of novel animal models of ALS and in evaluating therapeutic strategies for the treatment of the disease. Theo, originally from Cyprus, received his doctorate in pharmacology from Boston University School of Medicine for his thesis work on the neurotoxic effects of the psychostimulant methamphetamine.
Shumika Jean-Baptiste joined the ALS Therapy Development Institute in 2018. Shumika began as the front desk receptionist and transitioned on to the Finance department processing all donations and grants smoothly. She has a passion for financial operations and building her skills every day. Shumika has studied finance and is a graduate of the Year Up program which partners with Fortune 500 companies and 250+ corporate partners around the country. She has professional background working in investment operations, hedge funds and trading in her previous work experience at State Street Corporation. In her free time Shumika likes to encourage people to live the best life they can imagine, she loves to read motivational books, and is also working on one of her own. She also loves ice cream and watching good movies that Netflix has to offer.

“Enjoy the journey for it will only lead you towards better” – Shumika Jean-Baptiste
Joshua D. Kidd joined the ALS Therapy Development Institute in 2004. As a Research Associate, his job primarily involves studying the behavioral effects of different treatments in the SOD1-G93A Mouse model. Before coming to the Institute, Josh attended Minuteman Vocational Technical High School in Lexington, MA, where he earned a certificate in Graphic Design. Josh's family history with Huntington's Disease has given him a unique perspective and drives his desire to be a part of the effort to treat and cure devastating neurological diseases such as ALS. Since working at the Institute, he has earned his ALAT certification and is currently working towards a bachelor’s degree in biology at Northeastern University in Boston. Other than science, Josh is an avid animal lover and enjoys all things music and art. He currently calls Somerville his home.
Haley Knight joined the ALS Therapy Development Institute in 2017 and began working in the Precision Medicine Program. She is responsible for maintaining patient samples and patient-derived cell lines. After she received her Bachelor’s Degree of Arts, in Neuroscience/Pre-med, from Wheaton College (MA), Haley began working at ALS TDI due to her passion for the medical field and desire to work in a focused and dedicated research environment. She has a broad professional background working in labs focused in biochemistry, psychology, and neurology. Born and raised in Pawtucket, Rhode Island, she enjoys film, tennis, and traveling. “I am seeking, I am striving, I am in it with all my heart.” – Van Gogh
Allie Kosciak joined the ALS Therapy Development Institute in 2013 as a Tri-State Trek intern. After working with the ALS community during her internship, she became dedicated to the cause and rejoined the brand promotions team in 2014. Allie is now a part of the Augie's Quest team managing the ClubCorp Charity Classic program and assisting with many other Augie’s Quest events. Having always had a desire to work with people and help others, she is proud to now be able to continue this aspiration in her everyday life with the ALS Therapy Development Institute. Allie completed her undergraduate degree in marketing and public relations from Plymouth State University in 2014 and received a master’s degree in Project Management through Northeastern University in 2015. In her free time, she enjoys traveling and spending time with family and friends. "It's the journey not the destination that matters." - Unknown
Megan Kosciak joined the ALS Therapy Development Institute in 2017. She has joined the development team as Development Coordinator after completing the Tri-State Trek Internship in 2016. She loved the hope and inspiring power that the Trek demonstrated and wanted to work for the worthy cause that the ALS Therapy Development Institute proved to be. Megan graduated from Curry College in 2017 with a degree in Communication and has a personal background in professional technical theatre. A favorite quote of Megan's that lives in her office is, "Live fully. Challenge yourself. Be kind and generous. Inspire someone. Be grateful. Take the road less traveled. It’s never too late."
Beth Levine joined the ALS Therapy Development Institute in 2007. Beth brings 20 years of pharmaceutical and biotechnology experience to ALS Therapy Development Institute. As part of the Project Management team, it is her job to make sure projects run at maximum efficiency. She is also a member of the In Vivo Research group in which she is currently focused on studying the C9orf72 mutation. Beth is motivated everyday by the Institute’s unique approach to research based on one question – does this path lead us closer to a treatment or cure for ALS? Beth participates in many ALS fundraising events alongside people with ALS and their families and friends including riding in the Tri-State Trek and running in The Race for Research.
Dr. Lukashev joined the ALS Therapy Development Institute in 2013 with over 20 years of postgraduate research experience and 14 years of biotechnology industry experience. He has supported and led therapeutic discovery and development programs across all stages of drug development in therapeutic areas of neurology, oncology, immunology and fibrosis. His leadership of the research effort supporting clinical development of Tecfidera, an oral small molecule therapeutic recently approved by the FDA for treatment of multiple sclerosis was recognized by an Outstanding Scientific Achievement Award from Biogen Idec, Inc. Dr. Lukashev received a Ph.D. from the Russian Academy of Medical Sciences, and postdoctoral training at Johns Hopkins and University of California, San Francisco.
Emer Martin joined the ALS Therapy Development Institute in 2016. In her role as Communications and Development Specialist, Emer works to support the community with their local events and helps to produce community and donor communications in an effort to secure the vital funding required to continue the research here at ALS TDI. She is inspired by her colleagues across the team who demonstrate their commitment to putting an end to ALS every day. Previously, Emer has held roles in communications and HR. She is a graduate of Dublin City University and holds a Master’s degree in Science Communication. In her free time, Emer enjoys baking, exploring and crocheting.
Carlos joined the ALS Therapy Development Institute in 2005. Carlos is an animal technician on the science team. He has worked with animals since he was a young boy growing up on a farm in Colombia. His father was a veterinarian and taught Carlos how to care for the diverse animals on their farm. Carlos moved to the United States is 1991 and resides in Chelsea, MA, with his wife Juliana, and their children.
Jennifer McErlain joined the ALS Therapy Development Institute in 2015 as a Development Manager. Her passion for helping individuals affected by ALS and their families began during her time working with the Muscular Dystrophy Association where she served as Health Care Services Coordinator. Prior to MDA, Jennifer worked with a nonprofit to assist people living in affordable housing communities achieve greater self-sufficiency through education and social services. In her free time, she enjoys spending time outdoors, discovering new music, and eating other people's cooking. She resides in Northern Oakland, CA, with her husband, two children, and her cat. Jennifer is proud and honored to be part of the Development team at the Institute and fund cutting-edge research to end ALS. "Character is how you treat those who can do nothing for you." ~ Johann Wolfgang von Goethe
Maeve joined the ALS Therapy Development Institute in January 2012. She is originally from Ireland and holds a Degree in Business Administration. She previously worked as a project manager at Millennium Pharmaceuticals. Prior to this, she was employed at the Harvard Institute for International Development, following her role as an Administrator for a medical Non-Government Organization based in East Africa that responded to complex emergencies. In her spare time, Maeve enjoys hiking, tennis, horseback riding and cooking. She lives with her family and their dog, named Bono in Cambridge. As Director of Clinical Operations she is a member of the senior leadership team reporting directly to the CEO to deliver high quality patient outcomes and an exceptional patient experience while also focusing on efficiency and reducing costs. She directs, coordinates and monitors the operational, financial and personnel performance of the clinical department, and develops and implements department policies, initiatives and objectives to assist in achieving the Institute's vision and strategic goal of finding a therapeutic for ALS.
Andy Moreno joined the ALS Therapy Development Institute in 2002. At the Institute Andy is responsible for executing experimental drug studies in animal models of ALS. The fight of ALS patients and the dedication of their friends and families is what inspires Andy on a daily basis. Before joining the ALS Therapy Development Institute, Mr. Moreno worked for Harvard University Medical School. Andy attended the famous Cambridge Rindge and Latin School, the alma mater of Ben Affleck and Matt Damon, and thereafter Boston College. Andy, with his beautiful family, reside in Arlington, MA and they like to hike together in their free time.
Angel Chanchea-Moser joined the Augie's Quest Development team for the ALS Therapy Development Institute in July of 2015. Angel spent over 10 years with the Muscular Dystrophy Association where she spent most of her tenure as the Executive Director of the San Diego District, managing a large team of fundraising and health care staff servicing ALS and Muscular Dystrophy patients throughout San Diego County while maintaining a robust fundraising budget of $2 million. Angel finds great pleasure in engaging corporate donors, families, and community leaders in the mission of the Institute and has already made a large impact on the Augie's Quest team. Angel resides in San Diego with her husband, son and their dog.
Kaly Mueller joined the ALS Therapy Development Institute in 2018 after spending four years at Massachusetts General Hospital, where she researched the potential mechanisms behind neuronal death in Huntington's disease and ALS. As a member of the in vivo team, her current focus is providing detailed and accurate phenotypes for novel mouse models in hopes of incorporating them into future pre-clinical drug studies. She draws inspiration from the strength of ALS patients and their families, as well as the passion her coworkers display on a daily basis. Kaly graduated with a BS in Physiology from Marquette University in 2012, and an MS in Medical Science from Boston University in 2014. Outside of work, she is an avid baker and enjoys hiking and camping around the Northeast.

“You must strive to find your own voice because the longer you wait to begin, the less likely you are to find it at all.” – Robin Williams (Dead Poets Society)
Roxanne Murden joined the ALS Therapy Development Institute in 2014. In her role as a Finance Manager, Roxanne, along with her team, take care of processing every donation that comes to the Institute. Roxanne attended Community College on the North Shore. As a single mom of 2 – Lara who is 17 and Aragorn who is 13 – she is kept very busy. Outside of the Insitute, Roxanne has been member of the School’s PTA for over 8 years and has help roles as both its President and Vice President. In her free time, Roxanne loves going to the beach, reading good books and baking.
Melissa Nollstadt joined the ALS Therapy Development Institute in 2018. Melissa is the clinical data coordinator for the Precision Medicine Program. After working in pre-clinical research for therapeutic devices in biotech, she was inspired by the impressive research efforts underway at the ALS Therapy Development Institute and the impact they have had on the lives of patients and their families. Melissa studied public health sciences at the University of Massachusetts in Amherst, and went on to work as a research associate with a growing startup in Cambridge. In her free time, she enjoys reading, baking, and snowboarding.

“We are part of this universe; we are in this universe, but perhaps more important than both of those facts, is that the universe is in us.” – Neil deGrasse Tyson
Erika Norabuena joined the ALS Therapy Development Institute as part of the Translational Research group in 2017. She brings her expertise in human stem cells and neural differentiation to the group to work with patient samples and patient derived cell lines that will be used for assay development and drug screening studies. Erika moved from Miami, FL to Massachusetts for college and received her BA with honors in Biology from Mount Holyoke College. Prior to joining the group, she worked at the Harvard Department of Stem Cell and Regenerative Biology where, along with her lab managerial responsibilities, she worked in projects related to Parkinson’s disease, Schizophrenia and Spinal Muscular Atrophy. She decided to focus her research in ALS because of her prior research experience in motor neuron diseases and because of her admiration for Stephen Hawking. “One, remember to look up at the stars and not down at your feet. Two, never give up work. Work gives you meaning and purpose and life is empty without it. Three, if you are lucky enough to find love, remember it is there and don't throw it away." - S. Hawking.
Colette O'Neill joined ALS TDI as the Senior Director of Marketing, Communications and PR in April 2015. She has spent over fifteen years leading marketing and communications efforts at Boston area non-profits, as well as running her own practice in marketing strategy, design and production. This is her debut in the bio-medical space; she is humbled to work amongst a group of people at the Institute who are incredibly passionate about their work, and 100% dedicated to finding a cure for ALS. Originally from Ireland, Colette moved to Boston in 1999, and now lives on Boston's north shore with her family. She loves photography, people, contemporary art, film, biking and spontaneous adventures with her son.
Chelsea Owens joined the ALS Therapy Development Institute in 2018. In her role as Director of Events, Chelsea works with a team of event, production and communications specialists on sponsorship, logistics, marketing, production, digital promotion, volunteer/committee recruitment and engagement across all events in support of ALS TDI. Previously, Chelsea worked with JDRF New York City Chapter on the Signature Events team and worked for a time Off-Broadway in Manhattan as a Stage Manager. She graduated from Columbus State University with a BFA in Theatrical Design & Technology, and was born and raised in Atlanta, Georgia.

“I hope you live a life you’re proud of. And if you find that you are not, I hope you have the strength to start all over again.”
Dr. Steven Perrin joined the ALS Therapy Development in 2007 as part of historical collaboration between the Institute, the Muscular Dystrophy Association and Augie's Quest with the goal of developing a center of excellence for ALS drug development and translational research for neurodegenerative diseases. Steven is currently the Chief Executive Officer and Chief Scientific Officer. He earned his Ph.D. at Boston University Medical Center in the Department of Biochemistry. Steven moved into the pharmaceutical industry in 1997 holding positions at the Hoechst-Ariad, Genomics Center, Aventis Pharmaceuticals and more recently as Director of Molecular Profiling at Biogen Idec. Since joining the Institute, Steven has spearheaded the architectural design and execution of the world’s largest Precision Medicine Program. This innovative program has bridged the gap between early preclinical target discovery and the advancement of biomarkers and quantitative outcome measures for clinical development in ALS and other neurological disease indications. Under his leadership ALS TDI has assembled a world class scientific team that in the last seven years has brought two potential treatments into clinical development for ALS. He has accomplished these objectives by creating innovative business models bridging philanthropic investments in early stages of drug development with for virtual for profit biotechnology companies to manage clinical translation. Steven is a frequent invited participant and speaker in international conferences on computational biology, genomics, drug development, and neurodegeneration.
Alan Premasiri joined the ALS Therapy Development Institute in 2013. Alan graduated from Boston University with a degree in Neurobiology, and is applying to medical school. At the Institute, he does anything and everything related to the ALS-associated gene C9orf72. Alan is driven to work at the ALS Therapy Development Institute not only for his love of research, but also getting to meet inspiring people living with ALS and their families. Alan has ridden in the Tri-State Trek for two years alongside the ALS community. In his free time, Alan loves music, playing guitar, Ultimate Frisbee, tennis and anything science-related. "Do or do not, there is no try" -Yoda
Aarthi Ravi joined the ALS Therapy Development Institute in 2017 after completing her Masters in Biomedical Sciences at Northeastern University. She is part of the translational research team and her work includes stem cell culturing, cell sorting, flow cytometry and molecular cell biology techniques. Her previous work experiences as an intern at Harvard Innovations Lab and HuaCells Corporations includes cell culturing, assay development and biomedical devices development. She joined ALS TDI due to her passion to work in a research group and her aspiration to be part of a team working towards a cure for ALS. She completed her Bachelor’s degree in Engineering from India where she was born and raised. She loves travelling and visiting new places. “Everything is theoretically impossible, until it is done”- Robert A. Heinlein.
Clare Reich joined the ALS Therapy Development Institute in 2011. She is the Lead Data Management Analyst and lives in Oakland, CA. Clare works at the Institute with the hope of helping to save her brother and all people with ALS. Her brother, Corey, was diagnosed with ALS in 2007. Since his diagnosis, Clare and her family have been dedicated to raising funds for the Institute. Clare graduated from Colby College in May 2011 with a degree in history and was the captain of the women’s volleyball team. Clare enjoys traveling, reading, watching sports, and spending time with her family. “Life is too short to be anything but happy.” – Corey Reich
Carolyn Rodgers joined the ALS Therapy Development Institute in 2017. As the design and production specialist she designs visual content within the marketing and communications team. After collaborating with underfunded communities, Carolyn entered the nonprofit space to continue her dedication to bringing innovative visual communications to deserving causes. Carolyn has worked within a small tech startup, a university marketing office, and advertising agencies. She graduated from the University of Michigan with a BFA in Art & Design where she received awards in achievement in the area of disability, creative process, and leadership. Some of Carolyn's favorite things are painting colors and words, cooking brunch on the weekends, reading pretty books, and watching The Dick Van Dyke Show. "Solving any problem is more important than being right." - Milton Glaser
Ricardo (Ricky) Sanchez joined the ALS Therapy Development Institute in 2006 bringing more than twenty-nine years of experience in research and industrial histopathology to the team. Previously, he spent five years at Biogen Idec, Inc. as a histopathology supervisor. He also has over twenty years in research experience in nerve regeneration, inflammatory diseases, and cancer biology while working at Curis, and M.D. Anderson Cancer Center. Ricky received his BS in Biology and Histotechnology from Kean University of New Jersey. He and his family live in Andover, MA. "Together in the fight to end ALS”.
Shannon Shryne joined the ALS Therapy Development Institute in 2014. She oversees the Augie's Quest fundraising team and works with corporate partners and key supporters. She has over 20 years of experience cultivating and recruiting corporate partners and donors, creating cause marketing campaigns, and engaging supporters for maximum success. Shannon worked with Lynne and Augie Nieto in 2005 to create Augie's Quest, resulting in a network of ALS special events and cause marketing campaigns that have cumulatively raised over $50 million and are now being coordinated under the ALS Therapy Development Institute umbrella. Shannon serves on the Advisory Boards at CureSMA, the Kevin Turner Foundation and the California Fire Fighter Foundation. She received her BS from the University of Colorado in Boulder, and lives in Denver with her son Jacob and their dog, Wolfie.
Gretchen Simoneaux joined the ALS Therapy Development Institute in 2014 as a Development Director for the Augie's Quest Initiative. Gretchen was involved with Augie's Quest since its inception in 2005 at the Muscular Dystrophy Association working closely with Augie and Lynne Nieto. Her background includes over 12 years’ of experience in fundraising and development extensive work with large committees and corporate partners to produce successful fundraising events including gala's, golf tournaments, resulting in millions of dollars in revenue for ALS research. She enjoys working for a non-profit with a high-level of integrity that treats their donors and ambassadors as investors. Gretchen graduated from California Polytechnic University and lives in San Clemente, CA with her husband and two children.
Erin Stevens joined the ALS Therapy Development Institute in 2018. As a Development Manager, she spends her days partnering with families and individuals that are connected to the ALS Community with the same mission in supporting research and drug development ALS TDI. After volunteering at Tri-State Trek, Old Time Baseball, and participating in Corntoss, she was excited to join the Development Team within an organization she felt was vital to the future of ALS. Erin comes from a background of teaching a Middle & High School Math as well as working in operations for City Parks & Rec Departments and Chambers of Commerce. She is a graduate of the University of Florida with a Bachelor’s Degree in Hospitality. Erin enjoys travelling, playing sports, and spending time with friends and family. “Alone we can do so little, together we can do so much.”
Shawn Sullivan joined the ALS Therapy Development Institute in 2006 to help build web applications and the web presence for the Institute and many of its fundraising efforts. Specifically, Shawn is working to expand the web functionality of the Institute's drug discovery pipeline, the process database system we use to identify, evaluate, select and rank candidate drugs for testing. Shawn is also the lead developer for the Precision Medicine Program web portal which participants use to interact with their data. Shawn spent five years as a software developer at IMN Inc., where he helped clients such as Cisco Systems, Progress Software and Parametric Technology develop custom newsletters. He also has experience building Android apps, and in QA (quality assurance). Shawn attended Wentworth Institute of Technology.
Valerie Tassinari joined the ALS Therapy Development Institute in 2010. She came to Boston in 2009, earned her BA in Marine Science from Boston University in 2012, and now is a member of the in vivo team at the Institute. Her responsibilities include validating gene expression endpoints in drug studies and quantitative gene copy number analyses to facilitate high quality and interpretable in vivo target discovery and pharmacology studies. “Keep moving forward.” – Walt Disney
Ken Thompson joined the ALS Therapy Development Institute in 2000. A close friend of ALS patient Stephen Heywood, Ken discontinued his work in marine biology at the University of Alaska in 2000 to join ALS-TDI as a formulations scientist supporting the pharmacology team. At this time the lab was two small rooms in the depths of the New England Medical Center and the science team was six people strong. In his unique role at ALS TDI, Ken supports the In vivo team, daily lab operations and serves as clerk for the board of directors. Ken's previous research experience includes the molecular examination of starvation markers in larval stage cod at the University of Rhode Island. While at ALS TDI he has been coauthor on six publications.
Fernando G. Vieira, M.D. joined the ALS Therapy Development Institute in 2001. He is a research director focused on preclinical discovery and development of therapeutics for people with ALS. He works at the Institute because he believes it is the place where he can best work with others to help shape a world where an ALS diagnosis is no longer crippling. Fernando earned a bachelor’s degree in biological engineering from the University of Florida College of Engineering studied medicine at Harvard Medical School. He has dedicated his professional life to ending ALS. He has dedicated his personal life to being the best father he can be. “The essential thing ‘in heaven and earth’ is, apparently, that there should be a long obedience in the same direction; there thereby results, and has always resulted in the long run, something which has made life worth living.” –Friedrich Nietzche
Ben Wakefield joined the ALS Therapy Development Institute in 2009. Ben is responsible for maintaining existing web applications and implementing new web strategies. Previous to joining ALS TDI, Ben spent six years working in software and web development on an aerospace maintenance & engineering application. Prior to that, he worked for an information technology consulting firm in client/server based technologies. Ben is a graduate of the University of Maine.
Monica joined the ALS Therapy Development Institute in 2005. Formerly a member of Biogen's ALS discovery program, Monica has 28 years of basic research experience including stem cell research and animal surgeries in diabetes and Parkinson's disease. She spent five years focusing on HIV research at the New England Medical Center Hospital. She has extensive experience in the Cambridge biotechnology community, having held a senior position at Curis, where she filed successful patents. Monica is an expert in advanced confocal microscopy techniques, fluorescence, in-situ hybridization, immunohistochemistry, and cutting edge 3D histology using polymerized tissue sections. Her novel techniques include quantification of motor neurons, extraction of complex nerve assemblies, and imaging of ALS neuromuscular junctions. Monica loves to work out and is a CrossFit addict.
Yiding joined ALS Therapy Development Institute in 2015. She has 20 years’ experience in bench research in both biopharmaceuticals and academics, where she was involved in a broad range of technology for in vitro research. Her previous experience focused on mouse genetics modeling of human disease, inflammation kinase assays, cancer biology cell-based assays, siRNA DMPK study and cell automation. Her specialties include cell assays development and gene construction. In her free time, Yiding enjoys practicing meditation and yoga.